SCHEMBL23933724

SCHEMBL23933724

CC1CCN(NC(C)C(=O)O)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 1/20 0.36
ACHE P22303 1/20 0.36
POLB P06746 4/20 0.36
HTT P42858 2/20 0.35
USP2 O75604 1/20 0.35
HSP90AA1 P07900 1/20 0.35
GAA P10253 2/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NR4A1 P22736 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
LIPE Q05469 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL385711 0.79 L3MBTL1 (0.36) ALDH1A1NPC1POLBHTTGAA
SCHEMBL385712 0.79 L3MBTL1 (0.36) ALDH1A1NPC1POLBHTTGAA
SCHEMBL383047 0.78 L3MBTL1 (0.39) ALDH1A1MEN1KMT2AHTTGAA
SCHEMBL383046 0.78 L3MBTL1 (0.39) ALDH1A1MEN1KMT2AHTTGAA
SCHEMBL1457331 0.78 NOS2 (0.38) MEN1KMT2APOLBSMN1; SMN2
SCHEMBL1457333 0.78 NOS2 (0.38) MEN1KMT2APOLBSMN1; SMN2
SCHEMBL7403659 0.75 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2KDM4EHRH3
SCHEMBL7403657 0.75 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2KDM4EHRH3
SCHEMBL14706862 0.74 ALDH1A1 (0.38) ALDH1A1MEN1KMT2ANPC1ACHE
SCHEMBL15794748 0.74 CHRM5 (0.41) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242586-A1 RAS INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-08-03 US disclosed
EP-4138875-A1 RAS INHIBITORS AND USES THEREOF The Regents of the University of California (US) 2023-03-01 EP disclosed
WO-2021217019-A1 RAS INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242586-A1 RAS INHIBITORS AND USES THEREOF KRAS, NRAS, HRAS ALDH1A1 4073/4885MEN1 393/4885KMT2A 2616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.